Penn Medicine's 2021 Updates in Care of the Hematologic Malignancies Patient

 

Penn Medicine's 2021 Updates in Care of the Hematologic Malignancies Patient
A

CAR-T and IO for R/R MM in 2021: Is bb2121 Safe and Does It Improve ORR? Does Cilta-Cel Improve PFS? How to Improve Clinical Outcomes?

By Penn Medicine's 2021 Updates in Care of the Hematologic Malignancies Patient FEATURING Adam D. Cohen
By Penn Medicine's 2021 Updates in Care of the Hematologic Malignancies Patient FEATURING Adam D. Cohen
0 views
March 2, 2021
Comments 0
Login to view comments. Click here to Login

Featured Video

16:51
Incyte

Effects of PV Treatment on White Blood Cell Count and Thrombotic Risk

Feat. C. Harrison

Featured Video

24:08
Indy Hematology Review

Evaluation, Diagnosis, Prognostication, and Emerging Therapies for M…

Feat. A. Tefferi
Controversies and Update for Patient Care in Multiple Myeloma
17:23
Penn Medicine's 2021 Updates in Care of the Hematologic Malignancies Patient

UPenn Expert Analysis 40 y/o Patient With MM: How to Treat Systemica…

Feat. E. Stadtmauer, D. Vogl, A. Cohen, S. Wallace
10:17
Penn Medicine's 2021 Updates in Care of the Hematologic Malignancies Patient

UPenn Physicians Analyze a Challenging Case of MM: What Systemic The…

Feat. E. Stadtmauer, D. Vogl, A. Cohen, S. Wallace
15:36
Penn Medicine's 2021 Updates in Care of the Hematologic Malignancies Patient

CAR-T and IO for R/R MM in 2021: Is bb2121 Safe and Does It Improve …

Feat. A. Cohen
15:36
Penn Medicine's 2021 Updates in Care of the Hematologic Malignancies Patient

bsAb and IO for R/R MM in 2021: Are Teclistamab, Talquetamab, & …

Feat. A. Cohen
22:31
Penn Medicine's 2021 Updates in Care of the Hematologic Malignancies Patient

2021 Experimental Therapies for Relapsed Myeloma: Antibodies (Dara, …

Feat. D. Vogl